Santhera makes its second EU approval bid with Raxone
This article was originally published in Scrip
Executive Summary
Santhera Pharmaceuticals has made its second bid to get Raxone (idebenone), its treatment for Leber's hereditary optic neuropathy (LHON), approved in the EU.